

Review of: "An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN- β -1a and hydroxychloroquine in hospitalized patients with COVID-19 – Final results from the DisCoVeRy trial"

Adewale Owa

Potential competing interests: The author(s) declared that no potential competing interests exist.

This is a well conducted study carried out at an early part of an unprecedented pandemic. Congratulations to the authors. The study demonstrated that the repurposed medications showed no benefits on clinical improvement or reduction in viral shedding in Covid-19 infection.

It appears however that the serious adverse events reported in the intervention group may have been over-estimated. It is difficult to prove that all the serious adverse events reported were from the medications used and not from a progression of the disease itself.